Neuromuscular blockers and respiratory distress syndrome.
DOI:
https://doi.org/10.30445/rear.v12i8.845Keywords:
anesthesia, neuromuscular blockers, adult respiratory distress syndromeAbstract
Early use of neuromuscular blockers agents (NMBAs) in moderate-severe adult respiratory distress syndrome (ARDS) has previously been associated with a mortality decrease in the ACURASYS trial in 2010. However, the recently published ROSE study (Reevaluation of Systemic Early Neuromuscular Blockade) points out the disagreement with this practice.
References
- Early neuromuscular blockade in the acute respiratory distress syndrome. Moss M et al. The National Heart, Lung and Blood Institute PETAL Clinical Trials Network. N Engl J Med 2019; 380: 1997-2008.
- Neuromuscular blocking agents for acute respiratory distress syndrome: how did we get conflicting results? Torbic H, Krishnan S, Duggal A. Crit Care 2019; 23 (1): 305.
- Akoumianaki E, Lyazidi A, Rey N, et al. Mechanical ventilation-induced reverse-triggered breaths: a frequently unrecognized form of neuromechanical coupling. Chest 2013;143:927-938.
- Guerin C, Reignier J, Richard JC et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med 2013; 368: 2159-68.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Revista Electrónica AnestesiaR

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Envío y derechos de autor